Javascript must be enabled to continue!
Treatment Outcome of Childhood Hepatoblastoma: a Single Centre Experience in Bangladesh
View through CrossRef
Background: Hepatoblastoma is a rare malignant liver tumor that occurs almost exclusively in childhood. Although surgical resection is the foundation of curative therapy in hepatoblastoma, with the use of effective neoadjuvant and adjuvant chemotherapy, the survival of patients with hepatoblastoma has improved significantly.
Objective: To evaluate the clinical characteristics and treatment outcome of childhood hepatoblastoma treated at a tertiary care center in Bangladesh.
Methods: This observational study was conducted in the Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University, Bangladesh. The patient’s data were analyzed for clinical characteristics, treatment modalities, and survival outcomes.
Result: Twenty-four patients who were treated for Hepatoblastoma at our center were included in the study. Sixteen (66.5%) of them were male and M:F = 3:1 . The median age of presentation was 2.8 years, and 62.5% of patients were below 3 years of age. The median time of diagnosis after onset of symptoms was 8 months. An abdominal mass (90%) and abdominal pain (59.8%) were the most common presenting symptoms. The serum alpha-fetoprotein at the time of initial evaluation was raised in 96% of patients. The fetal histology (62.5%%) was the most common histological subtype. Two (8.4%), 7 (29 %), 8 (33.6%), and 7 (29 %) patients were found to have pre-treatment extent of tumor (PRETEXT) stages I, II, III, and IV, respectively. Seventeen (71 %) children were classified as standard risk, and 7 (29%) children as high risk. Complete resection of the primary tumor was possible in 11 (46%) patients. Out of the studied patients 12.5% developed relapse. Five-year overall survival was 66.6% and event-free survival was 58.3%.
Conclusion: The treatment outcome of hepatoblastoma at our center is comparable to other countries. The feasibility of all modalities of treatment, like liver transplantation in children, may improve the outcome.
Title: Treatment Outcome of Childhood Hepatoblastoma: a Single Centre Experience in Bangladesh
Description:
Background: Hepatoblastoma is a rare malignant liver tumor that occurs almost exclusively in childhood.
Although surgical resection is the foundation of curative therapy in hepatoblastoma, with the use of effective neoadjuvant and adjuvant chemotherapy, the survival of patients with hepatoblastoma has improved significantly.
Objective: To evaluate the clinical characteristics and treatment outcome of childhood hepatoblastoma treated at a tertiary care center in Bangladesh.
Methods: This observational study was conducted in the Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University, Bangladesh.
The patient’s data were analyzed for clinical characteristics, treatment modalities, and survival outcomes.
Result: Twenty-four patients who were treated for Hepatoblastoma at our center were included in the study.
Sixteen (66.
5%) of them were male and M:F = 3:1 .
The median age of presentation was 2.
8 years, and 62.
5% of patients were below 3 years of age.
The median time of diagnosis after onset of symptoms was 8 months.
An abdominal mass (90%) and abdominal pain (59.
8%) were the most common presenting symptoms.
The serum alpha-fetoprotein at the time of initial evaluation was raised in 96% of patients.
The fetal histology (62.
5%%) was the most common histological subtype.
Two (8.
4%), 7 (29 %), 8 (33.
6%), and 7 (29 %) patients were found to have pre-treatment extent of tumor (PRETEXT) stages I, II, III, and IV, respectively.
Seventeen (71 %) children were classified as standard risk, and 7 (29%) children as high risk.
Complete resection of the primary tumor was possible in 11 (46%) patients.
Out of the studied patients 12.
5% developed relapse.
Five-year overall survival was 66.
6% and event-free survival was 58.
3%.
Conclusion: The treatment outcome of hepatoblastoma at our center is comparable to other countries.
The feasibility of all modalities of treatment, like liver transplantation in children, may improve the outcome.
Related Results
SNHG9 Promotes the Hepatoblastoma Tumorigenesis via miR-23a-5p/Wnt3a Axis
SNHG9 Promotes the Hepatoblastoma Tumorigenesis via miR-23a-5p/Wnt3a Axis
Abstract
Background: Hepatoblastoma is common hepatic tumors occurring children between 0 – 5 years. Accumulating studies has shown lncRNA potential role in distinct cancer...
The Genetic Changes of Hepatoblastoma
The Genetic Changes of Hepatoblastoma
Hepatoblastoma is the most common malignant liver cancer in childhood. The etiology of hepatoblastoma remains obscure. Hepatoblastoma is closely related to genetic syndromes, hinti...
Uptake of Lipiodol™–cytotoxic conjugates by hepatoblastoma cells
Uptake of Lipiodol™–cytotoxic conjugates by hepatoblastoma cells
Abstract
Background
Improvements in the management of children with hepatoblastoma have followed advances made in cytotoxic agen...
Osoby niejednokrotnie przebywające w izbie wytrzeźwień
Osoby niejednokrotnie przebywające w izbie wytrzeźwień
In Poland we have at present in towns 29 detoxication centres with 1,226 beds; people found by the police in public places in a state of intoxication are more and more often taken ...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Novel Small Molecular Compound AE-848 Showed Potent Inhibitory Activity Against Human Hepatoblastoma Cells
Novel Small Molecular Compound AE-848 Showed Potent Inhibitory Activity Against Human Hepatoblastoma Cells
Abstract
Purpose
AE-848/33345007, is a novel small molecular compound that was independently synthesized by our laboratory. The...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Reappraisal of liver resection as an alternative to transplantation in locally advanced hepatoblastoma: A systematic review and analysis of pooled individual patient data
Reappraisal of liver resection as an alternative to transplantation in locally advanced hepatoblastoma: A systematic review and analysis of pooled individual patient data
Abstract
Background
There is ongoing debate regarding liver transplantation (LT) versus liver resection (LR) for locally ...

